Inventor · disambiguated record
Jose Aiguade Bosch
Also filed as: AIGUADE BOSCH JOSE
9 granted patents·1 pending application·50 citations·filing 2006–2017
86Inventor score
Technology areasA61P
Top patents by PatentIndex Score
10 records- 0187US9233108B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2012·Granted Jan 12, 2016·9 cites·3 claims
- 0285US7855202B2Imidazopyridine derivatives as A2B adenosine receptor antagonistsALMIRALL LAB·Filed 2006·Granted Dec 21, 2010·16 cites·9 claims
- 0381US9315463B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesPRAT QUINONES MARIA·Filed 2011·Granted Apr 19, 2016·15 cites·25 claims
- 0479US9757383B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2015·Granted Sep 12, 2017·2 cites·7 claims
- 0579US9549934B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2015·Granted Jan 24, 2017·2 cites·3 claims
- 0675US10005771B2Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2015·Granted Jun 26, 2018·2 cites·26 claims
- 0774US9643961B2Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2016·Granted May 9, 2017·2 cites·3 claims
- 0867US9518050B2Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activityALMIRALL SA·Filed 2013·Granted Dec 13, 2016·2 cites·46 claims
- 0960US10300072B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2017·Granted May 28, 2019·0 cites·24 claims
- 1042US2010105723A15-PHENYL-6-PYRIDIN-4-YL-1,3-DIHYDRO-2H-IMIDAZO[4,5-b]PYRIDIN-2-ONE DERIVATIVES USEFUL AS A2B ADENOSINE RECEPTOR ANTAGONISTSAIGUADE BOSCH JOSE·Filed 2007·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →